A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

CJC-1295 DAC, a synthetic peptide analog of growth hormone-releasing hormone (GHRH), has been a subject of considerable ...

Tharimmune (THAR) announced that the European Patent Office intends to grant the Company a patent covering biodegradable polymeric ...

Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 analog with unique ...

SAN FRANCISCO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of ...

Inspired by Resident Evil 4, Dead Space, Silent Hill, and the superb Signalis, new Steam horror game Scarlet Lake is ...

89bio intends to use the net proceeds from this proposed offering to fund ongoing clinical activities and development of ...

Tharimmune, Inc. (NASDAQ:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announced today ...

Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets ...

MET-097i showed a 7.5% reduction in body weight from baseline at day 36 and a 380-hour half-life. Following this positive clinical ... peptides and developed through twenty years of empirical ...

The case law distinguishes between so-called “unpredictable arts” (e.g., the biological, chemical, and pharmaceutical arts) ...

Invivyd reports clinical efficacy data from CANOPY phase 3 trial of pemivibart: Waltham, Massachusetts Friday, November 15, 2024, 18:00 Hrs [IST] Invivyd, Inc, a biopharmaceutical ...